https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38153132&retmode=xml&tool=Litmetric&email=readroberts32@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38153132</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0392-856X</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Clinical and experimental rheumatology</Title><ISOAbbreviation>Clin Exp Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Treatment of refractory psoriasis with dermatomyositis using upadacitinib.</ArticleTitle><Pagination><StartPage>458</StartPage><EndPage>459</EndPage><MedlinePgn>458-459</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.55563/clinexprheumatol/ki4jbt</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zining</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Bingyang</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Xi'an International Medical Center Hospital, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Hailong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Civil Aviation, Xi'an Hospital, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Shuhong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jiawen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. jiawen702@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Exp Rheumatol</MedlineTA><NlmUniqueID>8308521</NlmUniqueID><ISSNLinking>0392-856X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4RA0KN46E0</RegistryNumber><NameOfSubstance UI="C000613732">upadacitinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003882" MajorTopicYN="Y">Dermatomyositis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011565" MajorTopicYN="Y">Psoriasis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006575" MajorTopicYN="N">Heterocyclic Compounds, 3-Ring</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>28</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>28</Day><Hour>8</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38153132</ArticleId><ArticleId IdType="doi">10.55563/clinexprheumatol/ki4jbt</ArticleId><ArticleId IdType="pii">20161</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>